THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Biogen MS drug gets lift from reports

Medical journal suggests Tysabri may make a return

By Jeffrey Krasner
Globe Staff / June 10, 2005

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biogen Idec Inc.'s drug Tysabri might be safely given to multiple sclerosis patients if they are carefully monitored for an often fatal brain disease, according to articles in The New England Journal of Medicine. (Full article: 914 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass